Latest Anticonvulsants Stories

The substitution of brand-name antiepileptic drugs with cheaper generic equivalents has been an ongoing point of contention among doctors, federal officials and people with epilepsy. The U.S. Food and Drug Administration claims generic antiepileptic drugs have the same dosage, purity and strength as their brand-name counterparts and the two are interchangeable. But doctors and people with epilepsy remain concerned, citing widespread reports of individuals suffering seizures after switching...

Drug delivery directly into muscle using an autoinjector is faster and may be more effective in stopping prolonged seizures, according to a study sponsored by the National Institutes of Health and conducted by a Wayne State University School of Medicine researcher. The trial compared the effectiveness of two Federal Drug Administration-approved anti-seizure medications and how they are administered to patients suffering prolonged seizures before they arrive at hospitals. The Rapid...

DETROIT, Feb. 16, 2012 /PRNewswire-USNewswire/ -- Drug delivery directly into muscle using an autoinjector is faster and may be more effective in stopping prolonged seizures, according to a study sponsored by the National Institutes of Health and conducted by a Wayne State University School of Medicine researcher. The trial compared the effectiveness of two Federal Drug Administration-approved anti-seizure medications and how they are administered to patients suffering prolonged...

New research, published in the New England Journal of Medicine, finds that when a person is experiencing a prolonged seizure, quick medical intervention is critical, becoming harder to stop the seizure with each passing minute, placing the patient at risk of severe brain damage and death. It is for this reason that paramedics are trained to administer anticonvulsive medications as soon as possible -- typically giving them intravenously before arriving at the hospital. But according to...

In Jan 25th 2012, Abbott Laboratories (the company manufacturing Depakote) reported that 2011 selling, general and administrative expense report includes $1.5 billion of litigation reserves related to ongoing settlement discussions in the investigation by the U.S. Department of Justice, through the U.S. Attorney for the Western District of Virginia, related to Depakote. Depakote is a drug most commonly prescribed for psychiatric conditions like manic depressive disorder (bipolar disorder)...

SAN DIEGO, Feb. 6, 2012 /PRNewswire/ -- Neurelis, Inc. today announced that the United States Food and Drug Administration (FDA) has cleared an Investigational New Drug application (IND) to commence clinical trials advancing the development of NRL-1 for the treatment of acute breakthrough seizures. Following initial pre-IND discussions with FDA in late 2011, Neurelis filed the IND based upon the encouraging human pharmacokinetic results seen when comparing absolute...

PITTSBURGH, Jan. 19, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its Mylan Institutional business has launched Levetiracetam in Sodium Chloride Injection, 500 mg/100 mL, 1000 mg/100 mL and 1500 mg/100 mL, for intravenous use. Mylan's launch of this new product, which has been approved by the U.S. Food and Drug Administration (FDA), marks the first time that multiple strengths (500 mg, 1000 mg and 1500 mg) of premixed Levetiracetam will be...

Tokyo, Jan 16, 2012 - (JCN Newswire) - Nobelpharma Co. Ltd and Eisai Co. Ltd announced today that they will launch the anticonvulsant agent Fostoin 750 mg for Injection (fosphenytoin sodium hydrate, "fostoin") on January 17. Developed in Japan by Nobelpharma, Fostoin will be marketed by Eisai and co-promoted by both companies under a previously concluded marketing agreement.Fostoin is a water-soluble prodrug of phenytoin injection, a drug that has long been used...

CINCINNATI, Jan. 12, 2012 /PRNewswire/ -- Prasco® Laboratories announced today it has entered into an agreement with Shire (NASDAQ: SHPGY) for the distribution in the U.S. of the Authorized Generic version of Carbatrol® (Carbamazepine) Extended-Release Capsules in 100 mg, 200 mg and 300 mg strengths. Carbamazepine Extended-Release Capsules are AB-rated, therapeutically equivalent and substitutable for the brand Carbatrol®. The product will be distributed in the U.S. under the...

The Consumer Justice Foundation, whose Web site URL can be found at http://www.depakotebirthinjury.com, is a for-profit corporation staffed by a team of professional consumer advocates whose mission is to provide information for consumers concerning the potential dangers of certain prescription medications by way of free online educational resources. The CJF hereby alerts the public of the results of a survey concerning women who used hormonal birth control methods in conjunction with...